LENSAR (LNSR) Competitors $12.50 -0.26 (-2.04%) Closing price 08/14/2025 04:00 PM EasternExtended Trading$12.52 +0.02 (+0.16%) As of 08/14/2025 04:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock LNSR vs. BVS, SMLR, ZIMV, AVNS, KIDS, CBLL, TMCI, DCTH, SNWV, and BFLYShould you be buying LENSAR stock or one of its competitors? The main competitors of LENSAR include Bioventus (BVS), Semler Scientific (SMLR), ZimVie (ZIMV), AVANOS MEDICAL (AVNS), OrthoPediatrics (KIDS), CeriBell (CBLL), Treace Medical Concepts (TMCI), Delcath Systems (DCTH), Sanuwave Health (SNWV), and Butterfly Network (BFLY). These companies are all part of the "medical equipment" industry. LENSAR vs. Its Competitors Bioventus Semler Scientific ZimVie AVANOS MEDICAL OrthoPediatrics CeriBell Treace Medical Concepts Delcath Systems Sanuwave Health Butterfly Network Bioventus (NYSE:BVS) and LENSAR (NASDAQ:LNSR) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their risk, analyst recommendations, earnings, media sentiment, dividends, profitability, institutional ownership and valuation. Do institutionals & insiders have more ownership in BVS or LNSR? 62.9% of Bioventus shares are held by institutional investors. Comparatively, 40.2% of LENSAR shares are held by institutional investors. 33.0% of Bioventus shares are held by company insiders. Comparatively, 38.5% of LENSAR shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. Which has more risk & volatility, BVS or LNSR? Bioventus has a beta of 0.83, meaning that its share price is 17% less volatile than the S&P 500. Comparatively, LENSAR has a beta of 0.5, meaning that its share price is 50% less volatile than the S&P 500. Is BVS or LNSR more profitable? Bioventus has a net margin of -7.11% compared to LENSAR's net margin of -84.49%. Bioventus' return on equity of 15.61% beat LENSAR's return on equity.Company Net Margins Return on Equity Return on Assets Bioventus-7.11% 15.61% 4.01% LENSAR -84.49%-737.30%-72.60% Which has better valuation and earnings, BVS or LNSR? LENSAR has lower revenue, but higher earnings than Bioventus. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBioventus$564.14M1.07-$156.23MN/AN/ALENSAR$53.49M2.79-$31.40M-$4.21-2.97 Do analysts prefer BVS or LNSR? Bioventus currently has a consensus price target of $13.75, indicating a potential upside of 87.33%. LENSAR has a consensus price target of $15.00, indicating a potential upside of 20.00%. Given Bioventus' stronger consensus rating and higher probable upside, equities analysts plainly believe Bioventus is more favorable than LENSAR.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Bioventus 0 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.75LENSAR 0 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Does the media favor BVS or LNSR? In the previous week, Bioventus had 7 more articles in the media than LENSAR. MarketBeat recorded 8 mentions for Bioventus and 1 mentions for LENSAR. Bioventus' average media sentiment score of 0.42 beat LENSAR's score of -0.28 indicating that Bioventus is being referred to more favorably in the media. Company Overall Sentiment Bioventus Neutral LENSAR Neutral SummaryBioventus beats LENSAR on 11 of the 15 factors compared between the two stocks. Get LENSAR News Delivered to You Automatically Sign up to receive the latest news and ratings for LNSR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding LNSR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart LNSR vs. The Competition Export to ExcelMetricLENSARMED INSTRUMENTS IndustryMedical SectorNASDAQ ExchangeMarket Cap$152.29M$7.00B$5.61B$9.84BDividend YieldN/A1.30%4.61%4.07%P/E Ratio-2.9725.4830.2925.74Price / Sales2.7973.48470.61115.79Price / CashN/A21.9738.2159.48Price / Book-6.485.388.866.15Net Income-$31.40M$176.29M$3.25B$265.06M7 Day Performance-2.87%3.21%3.72%2.60%1 Month Performance-3.10%1.49%5.86%2.83%1 Year Performance207.88%10.20%30.49%25.58% LENSAR Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)LNSRLENSAR0.67 of 5 stars$12.50-2.0%$15.00+20.0%+211.7%$152.29M$53.49M-2.97110News CoverageNegative NewsBVSBioventus3.0384 of 5 stars$6.93+0.1%$13.75+98.4%-8.3%$569.26M$564.14M-11.361,200SMLRSemler Scientific3.3206 of 5 stars$35.28-2.4%$81.75+131.7%+25.1%$534.89M$56.29M14.52120Gap DownZIMVZimVie0.4513 of 5 stars$18.83+0.1%$17.75-5.7%+13.6%$530.46M$449.75M-26.901,770Short Interest ↑AVNSAVANOS MEDICAL1.7701 of 5 stars$10.52-2.8%N/A-51.4%$502.08M$687.80M-1.042,227Short Interest ↑KIDSOrthoPediatrics3.9917 of 5 stars$18.81-0.5%$34.14+81.5%-24.5%$474.14M$204.73M-10.51200CBLLCeriBell2.4965 of 5 stars$12.12-6.1%$32.14+165.2%N/A$473.33M$65.44M-4.05N/ATMCITreace Medical Concepts2.5218 of 5 stars$6.39+4.2%$9.83+53.9%+27.1%$387.25M$209.36M-8.09250DCTHDelcath Systems2.6732 of 5 stars$10.51+5.0%$24.50+133.1%+42.3%$350.16M$37.21M210.2060Short Interest ↑SNWVSanuwave Health2.5331 of 5 stars$42.74+7.5%$49.00+14.6%N/A$340.66M$32.63M-5.1840Earnings ReportGap UpHigh Trading VolumeBFLYButterfly Network2.5225 of 5 stars$1.37+2.6%$3.00+119.8%+50.4%$334.82M$82.06M-4.88460Gap Up Related Companies and Tools Related Companies Bioventus Competitors Semler Scientific Competitors ZimVie Competitors AVANOS MEDICAL Competitors OrthoPediatrics Competitors CeriBell Competitors Treace Medical Concepts Competitors Delcath Systems Competitors Sanuwave Health Competitors Butterfly Network Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:LNSR) was last updated on 8/15/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding LENSAR, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share LENSAR With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access